<DOC>
	<DOC>NCT00264160</DOC>
	<brief_summary>This open-label, multicenter trial will evaluate the efficacy and safety of treatment with AMN107 in chronic myelogenous leukemia (CML) patients that are resistant and/or intolerant to imatinib mesylate therapy.</brief_summary>
	<brief_title>Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Imatinib resistant or intolerant Philadelphia chromosomepositive CML in blast crisis, accelerated or chronic phase Males or females â‰¥ 18 years of age Impaired cardiac function Acute or chronic liver or renal disease Use of therapeutic coumadin Central nervous system (CNS) infiltration Additional protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>AMN107</keyword>
	<keyword>CML</keyword>
	<keyword>Bcr Abl</keyword>
	<keyword>cytogenetic response</keyword>
	<keyword>Chronic Myelogenous Leukemia (CML)</keyword>
	<keyword>imatinib mesylate</keyword>
</DOC>